James C Hamilton, the Chief Medical Officer of $ARWR, sold 10,000 shares of the company on 04-23-2026 for an estimated $750,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.2% of their shares of this class of stock. Following this trade, they now own 226,958 shares of this class of $ARWR stock.
$ARWR Insider Trading Activity
$ARWR insiders have traded $ARWR stock on the open market 46 times in the past 6 months. Of those trades, 0 have been purchases and 46 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- CHRISTOPHER RICHARD ANZALONE (Chief Executive Officer) has made 0 purchases and 13 sales selling 175,944 shares for an estimated $11,661,762.
- JAMES C HAMILTON (Chief Medical Officer) has made 0 purchases and 9 sales selling 60,164 shares for an estimated $3,926,561.
- PATRICK O'BRIEN (COO) has made 0 purchases and 12 sales selling 49,493 shares for an estimated $3,123,349.
- MAURO FERRARI has made 0 purchases and 2 sales selling 16,280 shares for an estimated $1,020,512.
- MICHAEL S PERRY sold 16,250 shares for an estimated $991,737
- VICTORIA VAKIENER has made 0 purchases and 3 sales selling 10,040 shares for an estimated $679,491.
- ADEOYE Y OLUKOTUN has made 0 purchases and 3 sales selling 10,000 shares for an estimated $676,623.
- WILLIAM D. WADDILL has made 0 purchases and 3 sales selling 8,367 shares for an estimated $566,038.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$ARWR Hedge Fund Activity
We have seen 241 institutional investors add shares of $ARWR stock to their portfolio, and 147 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,777,576 shares (-82.1%) from their portfolio in Q4 2025, for an estimated $383,573,270
- SLATE PATH CAPITAL LP removed 2,458,500 shares (-49.3%) from their portfolio in Q4 2025, for an estimated $163,219,815
- FRED ALGER MANAGEMENT, LLC added 1,526,164 shares (+497.4%) to their portfolio in Q4 2025, for an estimated $101,322,027
- MARSHALL WACE, LLP removed 1,312,985 shares (-91.4%) from their portfolio in Q4 2025, for an estimated $87,169,074
- SIREN, L.L.C. removed 1,169,404 shares (-43.8%) from their portfolio in Q4 2025, for an estimated $77,636,731
- BLACKROCK, INC. added 1,093,757 shares (+5.4%) to their portfolio in Q4 2025, for an estimated $72,614,527
- VESTAL POINT CAPITAL, LP added 900,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $59,751,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$ARWR Analyst Ratings
Wall Street analysts have issued reports on $ARWR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 12/17/2025
- Chardan Capital issued a "Buy" rating on 12/01/2025
- B of A Securities issued a "Buy" rating on 12/01/2025
- RBC Capital issued a "Outperform" rating on 11/19/2025
To track analyst ratings and price targets for $ARWR, check out Quiver Quantitative's $ARWR forecast page.
$ARWR Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 8 analysts offer price targets for $ARWR in the last 6 months, with a median target of $92.5.
Here are some recent targets:
- Michael Ulz from Morgan Stanley set a target price of $100.0 on 04/21/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $100.0 on 03/25/2026
- Madison El-Saadi from B. Riley Securities set a target price of $101.0 on 01/22/2026
- Edward Tenthoff from Piper Sandler set a target price of $110.0 on 01/13/2026
- Keay Nakae from Chardan Capital set a target price of $80.0 on 01/07/2026
- Andrea Tan from Goldman Sachs set a target price of $85.0 on 01/07/2026
- Luca Issi from RBC Capital set a target price of $80.0 on 12/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
